Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775
This study is recruiting at 18 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor, Adult
- Metastatic Breast Cancer
- Advanced Breast Cancer
- HER2 Mutation-Related Tumors
- HER2-positive Metastatic Breast Cancer
- KRAS Mutant Metastatic Colorectal Cancer
- Metastatic Lung Cancer
- Metastatic Colorectal Cancer
- Advanced Lung Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- HER2-positive Advanced Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- City of Hope Comprehensive Cancer Center · Duarte, CA
- University of California Los Angeles · Los Angeles, CA
- University of California San Diego Moores Cancer Center · San Diego, CA
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Indiana · 1
- Indiana University Simon Comprehensive Cancer Center · Indianapolis, IN
Massachusetts · 2
- Dana-Farber Cancer Insitute · Boston, MA
- Massachusetts General Hospital · Boston, MA
Missouri · 2
- St. Lukes Hospital of Kansas City · Kansas City, MO
- Washington University School of Medicine · St Louis, MO
New York · 2
- Columbia University Irving Medical Center · New York, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 4
- SCRI at Mary Crowley · Dallas, TX
- University of Texas Southwestern Medical Center · Dallas, TX
- The University of Texas MD Anderson Cancer Center · Houston, TX
- University of Texas San Antonio (UTSA) · San Antonio, TX
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Wisconsin · 1
- Wisconsin Institute for Medical Research · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.